CTXR | Citius Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.6785 - 0.7650
52 Week Range	0.6785 - 26.25
Beta	0.77
Implied Volatility	236.17%
IV Rank	90.59%
Day's Volume	169,682
Average Volume	309,001
Shares Outstanding	9,360,330
Market Cap	7,160,652
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-10-02

Valuation
Profitability
Growth
Health
P/E Ratio	-0.13
Forward P/E Ratio	-11.79
EPS	-5.82
1YR Price Target	6.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	22
Country	USA
Website	CTXR

Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

CTXR's peers: XFOR, HOOK, MREO, GRTX, ABOS, FBIO, EYEN, OCUP, INZY, TERN, DAWN, BLRX, ARDX, LXRX, MCRB, IBRX, ITRM

*Chart delayed

Analyzing fundamentals for CTXR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CTXR Fundamentals page.

Watching at CTXR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CTXR Technicals page.